» Articles » PMID: 37667096

MYEOV with High Frequencies of Mutations in Head and Neck Cancers Facilitates Cancer Cell Malignant Behaviors

Overview
Journal Biochem Genet
Specialty Molecular Biology
Date 2023 Sep 4
PMID 37667096
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer driver genes (CDGs) and the driver mutations disrupt the homeostasis of numerous critical cell activities, thereby playing a critical role in tumor initiation and progression. In this study, integrative bioinformatics analyses were performed based on a series of online databases, aiming to identify driver genes with high frequencies of mutations in head and neck cancers. Higher myeloma overexpressed (MYEOV) genetic variation frequency and expression level were connected to a poorer prognosis in head and neck cancer patients. MYEOV was dramatically upregulated within head and neck tumor samples and cells. Consistently, MYEOV overexpression remarkably enhanced the aggressiveness of head and neck cancer cells by promoting colony formation, cell invasion, and cell migration. Conversely, MYEOV knockdown attenuated cancer cell aggressiveness and inhibited tumor growth and metastasis in the oral orthotopic tumor model. In conclusion, MYEOV is overexpressed in head and neck cancer, with greater mutation frequencies correlating to a poorer prognosis in head and neck cancer patients. MYEOV serves as an oncogene in head and neck cancer through the promotion of tumor cell colony formation, invasion, and migration, as well as promoting tumor growth and metastasis in the oral orthotopic tumor model.

References
1.
Agrawal N, Frederick M, Pickering C, Bettegowda C, Chang K, Li R . Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333(6046):1154-7. PMC: 3162986. DOI: 10.1126/science.1206923. View

2.
Akhtar J, Wang Z, Yu C, Zhang Z . Effectiveness of local injection of lentivirus-delivered stathmin1 and stathmin1 shRNA in human gastric cancer xenograft mouse. J Gastroenterol Hepatol. 2014; 29(9):1685-91. DOI: 10.1111/jgh.12594. View

3.
Ausoni S, Boscolo-Rizzo P, Singh B, Da Mosto M, Spinato G, Tirelli G . Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer Metastasis Rev. 2016; 35(3):413-26. PMC: 5524458. DOI: 10.1007/s10555-016-9625-1. View

4.
Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 173(2):371-385.e18. PMC: 6029450. DOI: 10.1016/j.cell.2018.02.060. View

5.
Cao Z, Wang Z, Leng P . Aberrant N-cadherin expression in cancer. Biomed Pharmacother. 2019; 118:109320. DOI: 10.1016/j.biopha.2019.109320. View